Salvage Treatment With Venetoclax (Ven) and Hypomethylating Agents (HMA) for Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia (AML) Patients: Clinical Characteristics and Outcomes

被引：0
|
作者：
Ghorab, Ahmad [1 ]
Litzow, Mark [2 ]
Gangat, Naseema [2 ]
Al-Kali, Aref [2 ]
Shah, Mithun [2 ]
Murthy, Hemant [1 ]
Alkhateeb, Hasan [2 ]
Begna, Kebede [2 ]
Patnaik, Mrinal [2 ]
Foran, James [1 ]
Badar, Talha [1 ]
机构：
[1] Mayo Clin, Jacksonville, FL USA
[2] Mayo Clin, Rochester, MN USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
Relapsed/Refractory AML; FLT3; mutation; Hypomethylating Agents; Venetoclax; Clinical Outcomes;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
AML-497
引用
收藏
页码：S306 / S306
页数：1
相关论文
共 50 条
  • [31] Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
    Aldoss, Ibrahim
    Yang, Dongyun
    Pillai, Raju
    Sanchez, James F.
    Mei, Matthew
    Aribi, Ahmed
    Ali, Haris
    Sandhu, Karamjeet
    Al Malki, Monzr M.
    Salhotra, Amandeep
    Khaled, Samer
    Sun, Weili
    O'Donnell, Margaret
    Snyder, David
    Nakamura, Ryotaro
    Stein, Anthony S.
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (10) : E253 - E255
  • [32] Gilteritinib for the treatment of patients with FLT3 mutated relapsed or refractory acute myeloid leukemia
    Wang, Eunice S.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2019, 4 (03): : 105 - 112
  • [33] BURDEN OF ILLNESS (BOI) OF FLT3-MUTATED ACUTE MYELOID LEUKEMIA (AML)
    Sotak, M. L.
    Marin, M.
    Coombs, J.
    Schiller, G. J.
    Teitelbaum, A.
    VALUE IN HEALTH, 2012, 15 (04) : A101 - A102
  • [34] Venetoclax and hypomethylating agents inFLT3-mutated acute myeloid leukemia
    Aldoss, Ibrahim
    Zhang, Jianying
    Mei, Matthew
    Al Malki, Monzr M.
    Arslan, Shukaib
    Ngo, Dat
    Aribi, Ahmed
    Ali, Haris
    Sandhu, Karamjeet
    Salhotra, Amandeep
    Koller, Paul
    Khaled, Samer
    Artz, Andrew
    Snyder, David
    Nakamura, Ryotaro
    Forman, Stephen J.
    Stein, Anthony S.
    Marcucci, Guido
    Pullarkat, Vinod
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (10) : 1193 - 1199
  • [35] Relationship between patient-reported outcomes and clinical outcomes in patients with FLT3-mutated relapsed/refractory acute myeloid leukemia: results from the ADMIRAL study
    Cella, D.
    Ritchie, E.
    Fabbiano, F.
    Pigneux, A.
    Kanda, Y.
    Ivanescu, C.
    Pandya, B. J.
    Shah, M. V.
    SWISS MEDICAL WEEKLY, 2020, : 15S - 15S
  • [36] PATIENT-REPORTED OUTCOMES AND THEIR RELATIONSHIP WITH CLINICAL OUTCOMES IN PATIENTS WITH FLT3-MUTATED (FLT3MUT+) RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PHASE 3 ADMIRAL STUDY
    Cella, D.
    Ritchie, E.
    Fabbiano, F.
    Pigneux, A.
    Kanda, Y.
    Ivanescu, C.
    Pandya, B.
    Shah, M., V
    VALUE IN HEALTH, 2019, 22 : S531 - S531
  • [37] Hypomethylating Agent (HMA) Therapy and Venetoclax (VEN) with FLT3 Inhibitor "Triplet" Therapy Is Highly Active in Older/Unfit Patients with FLT3 Mutated AML
    Yilmaz, Musa
    Kantarjian, Hagop
    Short, Nicholas J.
    Konopleva, Marina
    Kadia, Tapan M.
    DiNardo, Courtney D.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Maiti, Abhishek
    Jabbour, Elias J.
    Issa, Ghayas C.
    Jain, Nitin
    Takahashi, Koichi
    Sasaki, Koji
    Ohanian, Maro
    Tang, Guilin
    Loghavi, Sanam
    Patel, Keyur
    Garcia-Manero, Guillermo
    Andreeff, Michael
    Ravandi, Farhad
    Daver, Naval
    BLOOD, 2021, 138
  • [38] Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
    Maiti, Abhishek
    DiNardo, Courtney D.
    Daver, Naval G.
    Rausch, Caitlin R.
    Ravandi, Farhad
    Kadia, Tapan M.
    Pemmaraju, Naveen
    Borthakur, Gautam
    Bose, Prithviraj
    Issa, Ghayas C.
    Short, Nicholas J.
    Yilmaz, Musa
    Montalban-Bravo, Guillermo
    Ferrajoli, Alessandra
    Jabbour, Elias J.
    Jain, Nitin
    Ohanian, Maro
    Takahashi, Koichi
    Thompson, Philip A.
    Loghavi, Sanam
    Montalbano, Kathryn S.
    Pierce, Sherry
    Wierda, William G.
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    BLOOD CANCER JOURNAL, 2021, 11 (02)
  • [39] Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
    Abhishek Maiti
    Courtney D. DiNardo
    Naval G. Daver
    Caitlin R. Rausch
    Farhad Ravandi
    Tapan M. Kadia
    Naveen Pemmaraju
    Gautam Borthakur
    Prithviraj Bose
    Ghayas C. Issa
    Nicholas J. Short
    Musa Yilmaz
    Guillermo Montalban-Bravo
    Alessandra Ferrajoli
    Elias J. Jabbour
    Nitin Jain
    Maro Ohanian
    Koichi Takahashi
    Philip A. Thompson
    Sanam Loghavi
    Kathryn S. Montalbano
    Sherry Pierce
    William G. Wierda
    Hagop M. Kantarjian
    Marina Y. Konopleva
    Blood Cancer Journal, 11
  • [40] Outcomes of Salvage Treatment in Patients with Acute Myeloid Leukemia (AML) with FLT3 Mutations
    Chen, Yiming
    Cortes, Jorge
    Lin, E.
    Ravandi, Farhad
    Faderl, Stefan
    Kadia, Tapan
    Kantarjian, Hagop M.
    Borthakur, Gautam
    BLOOD, 2009, 114 (22) : 820 - 820
12345